CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0185 (clinicaltrials.gov NCT No: NCT01781572)
Title:A Phase Ib/II, multicenter, open label, study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma
Principal Investigator:Rodabe N. Amaria
Treatment Agent: None; LEE011; MEK162
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
and dosing schedule of LEE011 that can be given with MEK162.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I/Phase II
Treatment Agents: None
LEE011
MEK162
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Array Biopharma
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Rodabe N. Amaria
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults